Abstract
Using polymerase chain reaction-assisted single-strand conformation polymorphism (PCR-SSCP) and immunohistochemical analyses, mutations in the p53 tumor suppressor gene were examined in 19 low-and high-grade gliomas. By PCR-SSCP and nucleotide analyses, p53 gene mutation was seen in 7 gliomas. Out of the 7 mutations, 3 were located at the CpG site of the previously proposed hot-spot codons 248 and 273, 2 were at codons 171 and 214 and the other 2 were in intron 5, 1 at the splice acceptor site and the other in the vicinity of the splice donor site. The latter 4 mutations have not, or only rarely, been observed in gliomas or in other tumors. However, their effect on the structural and functional alteration of the p53 protein was suggested by positive intranuclear p53 immunostaining in neoplastic cells in 3 mutations including the 1 at the splice acceptor site. In connection with glioma grading, the p53 gene mutation was shown to have occurred in both low- and high-grade gliomas, often in most of the neoplastic cells, as suggested by lack of distinct normal bands and ladders in SSCP and direct sequencing, respectively. The absence of recurrence and malignant transformation over a considerably long postoperative time in our low-grade glioma cases suggested that the p53 gene mutation might not be sufficient for the progression from low- to high-grade gliomas. The frequency of detection of mutation was 7/19(37%) by PCR-SSCP, 8/19(42%) by immunohistochemistry and 10/19(53%) by both methods. The results of PCR-SSCP and immunohistochemistry were consistent in 14 cases(73.7%), but not in 5 cases(26.3%). Thus, the use of both methods was recommended to survey the occurrence of p53 gene mutation more accurately.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tuinen P, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244: 217–221
Barbareschi M, Iuzzolino P, Pennella A, Allegranza A, Arrigoni G, Palma PD, Doglioni C (1992) p53 protein expression in central nervous system neoplasms. J Clin Pathol 45: 583–586
Blin N, Stafford DW (1976) A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 3: 2303–2308
Bruner JM, Saya H, Moser RP (1991) Immunocytochemical detection of p53 in human gliomas. Mod Pathol 4: 671–674
Chung R, Whaley J, Kley N, Anderson K, Louis D, Menon A, Hettlich C, Freiman R, Hedley-Whyte ET, Martuza R, Jenkins R, Yandell D, Seizinger BR (1991) TP53 gene mutations and 17p deletions in human astrocytomas. Genes Chromosomes Cancer 3: 323–331
Ehrlich M, Wang R Y-H (1981) 5-Methylcytosine in eukaryotic DNA. Science 212: 1350–1357
Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M (1989) Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 86: 8763–8767
Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine AJ (1988) Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8: 531–539
Finlay CA, Hinds PW, Levine AJ (1989) The p53 protooncogene can act as a suppressor of transformation. Cell 57: 1083–1093
Frankel RH, Bayona W, Koslow M, Newcomb EW (1992) p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res 52: 1427–1433
Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM (1992) p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 52: 674–679
Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253: 49–53
Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350: 427–428
Isobe M, Emanuel BS, Givol D, Oren M, Croce CM (1986) Localization of gene for human p53 tumour antigen to band 17p13. Nature 320: 84–85
Kernohan JW, Mabon RF, Svien HJ, Adson AW (1949) Symposium on a new and simplified concept of gliomas: simplified classification of gliomas. Proc Mayo Clinic 24: 71–75
Kleihues P, Burger PC, Scheithauer BW (1993) Histological typing of tumours of the central nervous system, 2nd edn. Springer-Verlag, Berlin Heidelberg New York Tokyo, pp 11–15
Lai M-Y, Chang H-C, Li H-P, Ku C-K, Chen P-J, Sheu J-C, Huang G-T, Lee P-H, Chen D-S (1993) Splicing mutations of the p53 gene in human hepatocellular carcinoma. Cancer Res 53: 1653–1656
Lamb P, Crawford L (1986) Characterization of the human p53 gene. Mol Cell Biol 6: 1379–1385
Louis DN, von Deimling A, Chung RY, Rubio M-P, Whaley JM, Eibl RH, Ohgaki H, Wiestler OD, Thor AD, Seizinger BR (1993) Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52: 31–38
Mashiyama S, Murakami Y, Yoshimoto T, Sekiya T, Hayashi K (1991) Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 6: 1313–1318
Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Koeffler HP (1986) Human p53 gene localized to short arm of chromosome 17. Nature 319: 783–784
Nakai H, Misawa S, Toguchida J, Yandell DW, Ishizaki K (1992) Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Res 52: 6588–6593
Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705–708
Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80–83
Orita M, Suzuki Y, Sekiya T, Hayashi K (1989) Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874–879
Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP (1993) Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736–2739
Rideout WM III, Coetzee GA, Olumi AF, Jones PA (1990) 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 249: 1288–1290
Sameshima Y, Akiyama T, Mori N, Mizoguchi H, Toyoshima K, Sugimura T, Terada M, Yokota J (1990) Point mutation of the p53 gene resulting in splicing inhibition in small cell lung carcinoma. Biochem Biophys Res Commun 173: 697–703
Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74: 5463–5467
Saxena A, Clark WC, Robertson JT, Ikejiri B, Oldfield EH, Ali IU (1992) Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas. Cancer Res 52: 6716–6721
Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B (1992) Clonal expansion of p53 mutant cells is associated with brain tomour progression. Nature 355: 846–847
Sommer SS, Cunningham J, McGovern RM, Saitoh S, Schroeder JJ, Wold LE, Kovach JS (1992) Pattern of p53 gene mutations in breast cancers of women of the midwestern United States. J Natl Cancer Inst 84: 246–252
Soussi T, de Fromentel CC, May P (1990) Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5: 945–952
Takagi S, Kimura M, Katsuki M (1992) A direct sequencing method for PCR products using λ exonuclease. Tanpakushitsu Kakusan Koso 37: 868–873 (in Japanese)
Takahashi T, D'Amico D, Chiba I, Buchhagen DL, Minna JD (1990) Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer. J Clin Invest 86: 363–369
von Deimling A, Eibl RH, Ohgaki H, Louis DN, von Ammon K, Petersen I, Kleihues P, Chung RY, Wiestler OD, Seizinger BR (1992) p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 52: 2987–2990
Wagata T, Shibagaki I, Imamura M, Shimada Y, Toguchida J, Yandell DW, Ikenaga M, Tobe T, Ishizaki K (1993) Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res 53: 846–850
Werness BA, Levine AJ, Howley PM (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76–79
Zarbl H, Sukumar S, Arthur AV, Martin-Zanca D, Barbacid M (1985) Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogeneses in rats. Nature 315: 382–385
Author information
Authors and Affiliations
Additional information
Supported in part by the Fujisawa Foundation
Rights and permissions
About this article
Cite this article
Koga, H., Zhang, S., Kumanishi, T. et al. Analysis of p53 gene mutations in low- and high-grade astrocytomas by polymerase chain reaction-assisted single-strand conformation polymorphism and immunohistochemistry. Acta Neuropathol 87, 225–232 (1994). https://doi.org/10.1007/BF00296737
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00296737